Capstone Therapeutics Corp
NASDAQ:CAPS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Capstone Therapeutics Corp (CAPS) under the Base Case is 4.94 USD per share.
Compared with the current market price of 1.44 USD, the stock appears
Undervalued by 71% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Capstone Therapeutics Does
Capstone Therapeutics Corp. is a biotechnology company. The company is headquartered in Tempe, Arizona. The firm is focused on development and commercialization of Apo E mimetic peptide AEM-28-14, through its investment in LipimetiX Development LLC. Apolipoprotein E is a 299 amino acid protein, which plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28-14, an analog of AEM-28, is a 28 amino acid mimetic of Apo E with an amino-hexanoic acid group and a phospholipid and both contain a domain, which anchors into a lipoprotein surface while…
- Headquarters
- United States of America US
- IPO date
- Feb 4, 1993
Balance Sheet
Continue CAPS Research
Decided on Capstone Therapeutics? Get an email when CAPS reaches the price you’d buy at. Free with an account.
What is the Intrinsic Value of one CAPS stock?
The intrinsic value for
Capstone Therapeutics Corp (CAPS) under the Base Case is 4.94 USD.
Is CAPS stock undervalued or overvalued?
Compared with the current market price of 1.44 USD, the stock appears Undervalued by 71% .